Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

被引：0
|
作者：
Cheng Huang
Xiao-Dong Zhu
Ying-Hao Shen
Dong Wu
Yuan Ji
Ning-Ling Ge
Ling-Li Chen
Chang-Jun Tan
Jian Zhou
Jia Fan
Hui-Chuan Sun
机构：
[1] Fudan University,Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital
[2] Fudan University,Department of Radiology, Zhongshan Hospital
[3] Fudan University,Department of Pathology, Zhongshan Hospital
[4] Fudan University,Department of Hepatic Oncology, Liver Cancer Institute and Zhongshan Hospital
来源：
Biomarker Research | / 9卷
关键词：
Lenvatinib; Carcinoma; Hepatocellular; Liver neoplasms; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
    Huang, Cheng
    Zhu, Xiao-Dong
    Shen, Ying-Hao
    Wu, Dong
    Ji, Yuan
    Ge, Ning-Ling
    Chen, Ling-Li
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    Sun, Hui-Chuan
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [2] Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
    Sun, H-C.
    Huang, C.
    Zhu, X-D.
    Shen, Y-H.
    Wu, D.
    Ge, N-L.
    Chen, Y.
    Tan, C-J.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [3] Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
    Zou, Jixue
    Huang, Peixin
    Ge, Ningling
    Xu, Xin
    Wang, Yanhong
    Zhang, Lan
    Chen, Yi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1898 - 1906
  • [4] Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Wu, Jia-Yi
    Yin, Zhen-Yu
    Bai, Yan-Nan
    Chen, Yu-Feng
    Zhou, Song-Qiang
    Wang, Shuang-Jia
    Zhou, Jian-Yin
    Li, Yi-Nan
    Qiu, Fu-Nan
    Li, Bin
    Yan, Mao-Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1233 - 1240
  • [5] The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma.
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Zhang, Jihai
    Dong, Zheng
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Yang, Yongping
    Zeng, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16152 - E16152
  • [6] Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
    Wu, Jiayi
    Wu, Junyi
    Li, Shuqun
    Luo, Mengchao
    Zeng, Zhenxin
    Li, Yinan
    Fu, Yangkai
    Li, Han
    Liu, Deyi
    Ou, Xiangye
    Lin, Zhongtai
    Wei, Shaoming
    Yan, Maolin
    BIOSCIENCE TRENDS, 2024, 18 (01) : 42 - 48
  • [7] Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
    Yi, Yong
    Sun, Bao-Ye
    Weng, Jia-Lei
    Zhou, Cheng
    Zhou, Chen-Hao
    Cai, Ming-Hao
    Zhang, Jing-Yun
    Gao, Hong
    Sun, Jian
    Zhou, Jian
    Fan, Jia
    Ren, Ning
    Qiu, Shuang-Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Zeng, Zhen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 847 - 861
  • [9] ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Dong, Zheng
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Yang, Yongping
    Zeng, Zhen
    HEPATOLOGY, 2022, 76 : S1305 - S1306
  • [10] Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis
    Song, Tianqiang
    Lang, Mengran
    Lu, Wei
    Zhang, Ti
    Li, Huikai
    Wu, Qiang
    Cui, Yunlong
    Zhang, Wei
    Li, Qiang
    Zang, Fenglin
    Xing, Wenge
    Ren, Shaohua
    Gan, Leijuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345